Log In
Print
BCIQ
Print
Print this Print this
 

Hetlioz, tasimelteon (VEC-162)

  Manage Alerts
Collapse Summary General Information
Company Vanda Pharmaceuticals Inc.
DescriptionMelatonin MT1 and MT2 receptor agonist
Molecular Target Melatonin MT1 receptor ; Melatonin MT2 receptor
Mechanism of ActionMelatonin MT2 receptor agonist; Melatonin MT1 receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationInsomnia
Indication DetailsTreat chronic insomnia; Treat circadian rhythm sleep disorder; Treat non-24-hour sleep wake disorder; Treat non-24-hour sleep wake disorder in blind patients without light perception; Treat transient insomnia
Regulatory Designation

U.S. - Orphan Drug (Treat non-24-hour sleep wake disorder in blind patients without light perception);
U.S. - Priority Review (Treat non-24-hour sleep wake disorder);
EU - Orphan Drug (Treat non-24-hour sleep wake disorder in blind patients without light perception)

Partner

Bristol-Myers Squibb Co.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today